PMID- 11494357
OWN - NLM
STAT- MEDLINE
DCOM- 20011011
LR  - 20151119
IS  - 0360-4012 (Print)
IS  - 0360-4012 (Linking)
VI  - 65
IP  - 3
DP  - 2001 Aug 1
TI  - Administration of FGF-2 to embryonic mouse brain induces hydrocephalic brain 
      morphology and aberrant differentiation of neurons in the postnatal cerebral 
      cortex.
PG  - 228-35
AB  - Fibroblast growth factor-2 (FGF-2) was injected into mouse cerebral ventricles at 
      embryonic day (E) 14 in utero and its effects on developing brain morphology and 
      expression of various cell- or differentiation-associated protein markers in the 
      cerebral cortex were examined. High doses of FGF-2 (200 or 300 ng) caused 
      encephalic alternations such as deformation of the calvarium, enlargement of the 
      ventricular spaces, and thinning of the cerebral cortex. There was no gross 
      abnormality in the alignment of the cerebral neuronal layers, however, both cell 
      number and cell density of the upper layers (II/III) and the lower layers (IV-VI) 
      of the cerebral cortex were increased. Brain-derived neurotrophic factor (BDNF), 
      tyrosine hydroxylase, nestin, and microtubule-associated protein 2 were 
      aberrantly or ectopically expressed in the deep areas of the cerebral cortex. A 
      substantial number of these cells coexpressed these antigens. These observations 
      demonstrate that a subpopulation of neurons in the cortical deep layer abnormally 
      differentiated or partly sustained their immature state following a single 
      administration of FGF-2 at E14. Developmental analysis of localization of 
      BDNF-positive cells suggested that the abnormality started around P5. 
      Furthermore, cell migration was not affected by FGF-2 administration. FGF-2 seems 
      to play predominant roles in the proliferation of neuronal precursors and in 
      neuronal differentiation in the developing mouse cerebral cortex even at 
      relatively late stages of brain neurogenesis.
CI  - Copyright 2001 Wiley-Liss, Inc.
FAU - Ohmiya, M
AU  - Ohmiya M
AD  - Laboratory of Molecular Biology, Gifu Pharmaceutical University, 
      Mitahora-higashi, Gifu 502-8585, Japan.
FAU - Fukumitsu, H
AU  - Fukumitsu H
FAU - Nitta, A
AU  - Nitta A
FAU - Nomoto, H
AU  - Nomoto H
FAU - Furukawa, Y
AU  - Furukawa Y
FAU - Furukawa, S
AU  - Furukawa S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Neurosci Res
JT  - Journal of neuroscience research
JID - 7600111
RN  - 0 (Biomarkers)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Intermediate Filament Proteins)
RN  - 0 (Microtubule-Associated Proteins)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (Nes protein, mouse)
RN  - 0 (Nestin)
RN  - 103107-01-3 (Fibroblast Growth Factor 2)
RN  - EC 1.14.16.2 (Tyrosine 3-Monooxygenase)
SB  - IM
MH  - Animals
MH  - Biomarkers
MH  - Brain-Derived Neurotrophic Factor/analysis
MH  - Cell Differentiation/drug effects
MH  - Cell Division/drug effects
MH  - Cell Movement
MH  - Cerebral Cortex/abnormalities/*drug effects/embryology/pathology
MH  - Fibroblast Growth Factor 2/administration & dosage/*pharmacology/physiology
MH  - Gestational Age
MH  - Hydrocephalus/*chemically induced/pathology
MH  - Injections, Intraventricular
MH  - Intermediate Filament Proteins/analysis
MH  - Mice
MH  - Mice, Mutant Strains
MH  - Microtubule-Associated Proteins/analysis
MH  - Nerve Tissue Proteins/analysis
MH  - Nestin
MH  - Neurons/*pathology
MH  - Tyrosine 3-Monooxygenase/analysis
EDAT- 2001/08/09 10:00
MHDA- 2001/10/12 10:01
CRDT- 2001/08/09 10:00
PHST- 2001/08/09 10:00 [pubmed]
PHST- 2001/10/12 10:01 [medline]
PHST- 2001/08/09 10:00 [entrez]
AID - 10.1002/jnr.1146 [doi]
PST - ppublish
SO  - J Neurosci Res. 2001 Aug 1;65(3):228-35. doi: 10.1002/jnr.1146.